Published in Cancer Res on November 30, 2010
Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. J Natl Cancer Inst (2013) 1.75
Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS J (2012) 1.14
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev (2013) 1.05
Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol (2011) 0.98
Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. Eur Radiol (2012) 0.92
Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer Med (2014) 0.92
Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia. Am J Physiol Heart Circ Physiol (2013) 0.90
Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug Discov Today (2014) 0.90
Expression of VEGF receptors on endothelial cells in mouse skeletal muscle. PLoS One (2012) 0.90
Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities. Front Pharmacol (2015) 0.89
Computational models of VEGF-associated angiogenic processes in cancer. Math Med Biol (2011) 0.87
A systems biology view of blood vessel growth and remodelling. J Cell Mol Med (2013) 0.86
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemother Pharmacol (2015) 0.84
A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback. J Math Biol (2013) 0.84
A two-compartment model of VEGF distribution in the mouse. PLoS One (2011) 0.84
Quantitative characterization of cellular membrane-receptor heterogeneity through statistical and computational modeling. PLoS One (2014) 0.80
A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation. MAbs (2015) 0.78
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol (2015) 0.78
Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: systems pharmacology approach. CPT Pharmacometrics Syst Pharmacol (2014) 0.77
Systems biology of the microvasculature. Integr Biol (Camb) (2015) 0.77
Molecular mechanism matters: Benefits of mechanistic computational models for drug development. Pharmacol Res (2015) 0.77
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget (2016) 0.76
Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice. PLoS One (2015) 0.76
The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance. Oncotarget (2016) 0.76
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia. MAbs (2015) 0.75
Divide and conquer, faster: speeding up molecular simulations. Biophys J (2015) 0.75
Multiphasic changes in systemic VEGF following intravitreal injections of ranibizumab in a child. Eye (Lond) (2015) 0.75
A computational analysis of in vivo VEGFR activation by multiple co-expressed ligands. PLoS Comput Biol (2017) 0.75
A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. Br J Cancer (2016) 0.75
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res (1995) 6.21
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Microvascular permeability. Physiol Rev (1999) 4.12
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Platelets actively sequester angiogenesis regulators. Blood (2008) 2.47
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol (2009) 2.41
Integrative mathematical oncology. Nat Rev Cancer (2008) 2.28
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A (2007) 2.19
Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina (2007) 2.09
Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer (2010) 1.92
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther (1999) 1.88
In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med (2007) 1.79
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer (2007) 1.61
A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol (2008) 1.50
Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest (1998) 1.36
Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res (2004) 1.16
The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res (2006) 1.14
Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov (2002) 1.13
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol (2007) 1.12
Complexation of VEGF with bevacizumab decreases VEGF clearance in rats. Pharm Res (2002) 1.05
Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol (2010) 1.02
The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling. PLoS Comput Biol (2009) 0.96
Targeting tumor angiogenesis. Semin Oncol (2009) 0.95
Comparison of the permeability surface product (PS) of the blood capillary wall in skeletal muscle tissue of various species and in vitro porous membranes using hydrophilic drugs. J Pharm Sci (2000) 0.87
Comment of article by Matsumoto Y. Retina (2008) 0.79
Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. J Natl Cancer Inst (2013) 1.75
A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med (2009) 1.59
A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2. J Biol Chem (2004) 1.51
A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol (2008) 1.50
Temporal and spatial variations of cell-free layer width in arterioles. Am J Physiol Heart Circ Physiol (2007) 1.46
Systems biology of vascular endothelial growth factors. Microcirculation (2008) 1.41
Computational fluid dynamic simulation of aggregation of deformable cells in a shear flow. J Biomech Eng (2005) 1.40
Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol (2003) 1.33
Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol (2011) 1.32
Multiscale models of angiogenesis. IEEE Eng Med Biol Mag (2009) 1.26
Effects of erythrocyte deformability and aggregation on the cell free layer and apparent viscosity of microscopic blood flows. Microvasc Res (2009) 1.24
Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Mol Cell Biol (2008) 1.21
Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol (2006) 1.21
Effect of aggregation and shear rate on the dispersion of red blood cells flowing in venules. Am J Physiol Heart Circ Physiol (2002) 1.20
VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. J Appl Physiol (1985) (2006) 1.20
A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1 alpha. J Cell Sci (2006) 1.20
Blood flow and cell-free layer in microvessels. Microcirculation (2010) 1.19
A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem (2007) 1.18
Experimental and theoretical studies of oxygen gradients in rat pial microvessels. J Cereb Blood Flow Metab (2008) 1.18
Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophys Chem (2007) 1.18
Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches. PLoS Comput Biol (2006) 1.17
A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci U S A (2008) 1.16
Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective. Antioxid Redox Signal (2008) 1.16
Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model. J Theor Biol (2005) 1.16
Theoretical analysis of biochemical pathways of nitric oxide release from vascular endothelial cells. Free Radic Biol Med (2006) 1.15
Red blood cell aggregation and dissociation in shear flows simulated by lattice Boltzmann method. J Biomech (2007) 1.14
Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS J (2012) 1.14
Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. Exp Cell Res (2010) 1.14
Effect of outer hair cell piezoelectricity on high-frequency receptor potentials. J Acoust Soc Am (2003) 1.13
Erythrocyte consumption of nitric oxide in presence and absence of plasma-based hemoglobin. Am J Physiol Heart Circ Physiol (2002) 1.13
Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. Am J Physiol Heart Circ Physiol (2005) 1.11
Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy. PLoS Comput Biol (2006) 1.10
Elongation, proliferation & migration differentiate endothelial cell phenotypes and determine capillary sprouting. BMC Syst Biol (2009) 1.10
Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia (2009) 1.10
A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS One (2009) 1.09
Contribution of nNOS- and eNOS-derived NO to microvascular smooth muscle NO exposure. J Appl Physiol (1985) (2004) 1.07
A computer-based method for determination of the cell-free layer width in microcirculation. Microcirculation (2006) 1.06
Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdiscip Rev Syst Biol Med (2010) 1.06
Wall shear stress differentially affects NO level in arterioles for volume expanders and Hb-based O2 carriers. Microvasc Res (2003) 1.05
Module-based multiscale simulation of angiogenesis in skeletal muscle. Theor Biol Med Model (2011) 1.04
Nitric oxide from nitrite reduction by hemoglobin in the plasma and erythrocytes. Nitric Oxide (2007) 1.03
Model of nitric oxide diffusion in an arteriole: impact of hemoglobin-based blood substitutes. Am J Physiol Heart Circ Physiol (2002) 1.03
Multi-scale computational models of pro-angiogenic treatments in peripheral arterial disease. Ann Biomed Eng (2007) 1.03
Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties. Biochem Biophys Res Commun (2007) 1.03
A reaction-diffusion model of basic fibroblast growth factor interactions with cell surface receptors. Ann Biomed Eng (2004) 1.02
Endothelial cell-dependent regulation of arteriogenesis. Circ Res (2013) 1.00
A computational model of oxygen transport in skeletal muscle for sprouting and splitting modes of angiogenesis. J Theor Biol (2006) 1.00
Calculations of oxygen transport by red blood cells and hemoglobin solutions in capillaries. Artif Cells Blood Substit Immobil Biotechnol (2002) 1.00
Relationship between erythrocyte aggregate size and flow rate in skeletal muscle venules. Am J Physiol Heart Circ Physiol (2003) 1.00
Intracoronary administration of FGF-2: a computational model of myocardial deposition and retention. Am J Physiol Heart Circ Physiol (2004) 1.00
Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Front Oncol (2013) 0.99
A computational model of oxygen delivery by hemoglobin-based oxygen carriers in three-dimensional microvascular networks. J Theor Biol (2007) 0.98
Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol (2011) 0.98
Three autocrine feedback loops determine HIF1 alpha expression in chronic hypoxia. Biochim Biophys Acta (2007) 0.97
Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise. Am J Physiol Heart Circ Physiol (2007) 0.97
An immersed boundary lattice Boltzmann approach to simulate deformable liquid capsules and its application to microscopic blood flows. Phys Biol (2007) 0.97
Aggregate formation of erythrocytes in postcapillary venules. Am J Physiol Heart Circ Physiol (2004) 0.96
Theoretical models for coronary vascular biomechanics: progress & challenges. Prog Biophys Mol Biol (2010) 0.96
Selective activation of sphingosine 1-phosphate receptors 1 and 3 promotes local microvascular network growth. Tissue Eng Part A (2010) 0.96
The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling. PLoS Comput Biol (2009) 0.96
Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia (2013) 0.96
A theoretical model of nitric oxide transport in arterioles: frequency- vs. amplitude-dependent control of cGMP formation. Am J Physiol Heart Circ Physiol (2003) 0.94
Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. Int J Biochem Cell Biol (2011) 0.94
Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis. BMC Syst Biol (2011) 0.94
Multiscale imaging and computational modeling of blood flow in the tumor vasculature. Ann Biomed Eng (2012) 0.94
Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer. PLoS One (2013) 0.94
Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer (2010) 0.93
VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. Am J Physiol Heart Circ Physiol (2010) 0.93
Computational modeling of interacting VEGF and soluble VEGF receptor concentration gradients. Front Physiol (2011) 0.93
Hypotonic swelling of salicylate-treated cochlear outer hair cells. Hear Res (2007) 0.93
Effect of erythrocyte aggregation at normal human levels on functional capillary density in rat spinotrapezius muscle. Am J Physiol Heart Circ Physiol (2005) 0.92
Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. PLoS One (2010) 0.92
Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer Med (2014) 0.92
Vascular smooth muscle NO exposure from intraerythrocytic SNOHb: a mathematical model. Antioxid Redox Signal (2007) 0.92
Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. J Med Chem (2011) 0.91
An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator. Biotechnol Bioeng (2002) 0.90
Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia. Am J Physiol Heart Circ Physiol (2013) 0.90
Novel anti-angiogenic peptides derived from ELR-containing CXC chemokines. J Cell Biochem (2008) 0.90
A model of nitric oxide capillary exchange. Microcirculation (2003) 0.90
Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport. Physiol Genomics (2009) 0.90
Expression of VEGF receptors on endothelial cells in mouse skeletal muscle. PLoS One (2012) 0.90
Anti-angiogenic peptides identified in thrombospondin type I domains. Biochem Biophys Res Commun (2007) 0.89
Blood-plasma separation in Y-shaped bifurcating microfluidic channels: a dissipative particle dynamics simulation study. Phys Biol (2012) 0.89
Monte Carlo simulations of VEGF binding to cell surface receptors in vitro. Biochim Biophys Acta (2005) 0.88
Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells. Int J Biochem Cell Biol (2007) 0.87
Gene therapy from the perspective of systems biology. Curr Opin Mol Ther (2010) 0.87